The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer

S. Honda, M. Toi, S. Shimizu, K. Hayashi, T. Tominaga

Research output: Contribution to journalArticle

Abstract

In Japan, 5-FU/5-FU derivatives or the combination therapy of CAF (cyclophosphamide, CPA; adriamycin, ADM; 5-fluorouracil; 5-FU) have been commonly used for the adjuvant treatment of breast cancer. Recently, a combination of CEF (CPA; Epirubicin, EPI; 5-FU) has come to the stage of adjuvant setting, because the cardiotoxicity was reduced in EPI. In this study, we investigated the feasibility of 6 cycles of CEF (CPA 700 mg/m2 EPI 70 mg/m2, 5-FU 700 mg/m2; day 1 iv every 3-4 weeks) in the adjuvant treatment of primary breast cancer patients with nodal involvements. All 12 patients completed 6 cycles of CEF within 8 months. The median treatment duration was 6.2 months. More than Grade III side effects of neutropenia, nausea/vomiting and alopecia were observed in 7/12 (58.3%), 5/12 (41.7%) and 12/12 (100%), respectively. No serious side effects, including cardiotoxicity, were shown. CEF seems to be a feasible regimen as an adjuvant treatment for breast cancer.

Original languageEnglish (US)
Pages (from-to)679-683
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume24
Issue number6
StatePublished - Sep 24 1997

Fingerprint

Epirubicin
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Therapeutics
Alopecia
Neutropenia
Doxorubicin
Nausea
Vomiting
Japan

Keywords

  • Adjuvant chemotherapy
  • CEF
  • Epirubicin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer. / Honda, S.; Toi, M.; Shimizu, S.; Hayashi, K.; Tominaga, T.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 24, No. 6, 24.09.1997, p. 679-683.

Research output: Contribution to journalArticle

@article{3662f2c88ea841f398db802d6a62daf2,
title = "The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer",
abstract = "In Japan, 5-FU/5-FU derivatives or the combination therapy of CAF (cyclophosphamide, CPA; adriamycin, ADM; 5-fluorouracil; 5-FU) have been commonly used for the adjuvant treatment of breast cancer. Recently, a combination of CEF (CPA; Epirubicin, EPI; 5-FU) has come to the stage of adjuvant setting, because the cardiotoxicity was reduced in EPI. In this study, we investigated the feasibility of 6 cycles of CEF (CPA 700 mg/m2 EPI 70 mg/m2, 5-FU 700 mg/m2; day 1 iv every 3-4 weeks) in the adjuvant treatment of primary breast cancer patients with nodal involvements. All 12 patients completed 6 cycles of CEF within 8 months. The median treatment duration was 6.2 months. More than Grade III side effects of neutropenia, nausea/vomiting and alopecia were observed in 7/12 (58.3{\%}), 5/12 (41.7{\%}) and 12/12 (100{\%}), respectively. No serious side effects, including cardiotoxicity, were shown. CEF seems to be a feasible regimen as an adjuvant treatment for breast cancer.",
keywords = "Adjuvant chemotherapy, CEF, Epirubicin",
author = "S. Honda and M. Toi and S. Shimizu and K. Hayashi and T. Tominaga",
year = "1997",
month = "9",
day = "24",
language = "English (US)",
volume = "24",
pages = "679--683",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "6",

}

TY - JOUR

T1 - The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer

AU - Honda, S.

AU - Toi, M.

AU - Shimizu, S.

AU - Hayashi, K.

AU - Tominaga, T.

PY - 1997/9/24

Y1 - 1997/9/24

N2 - In Japan, 5-FU/5-FU derivatives or the combination therapy of CAF (cyclophosphamide, CPA; adriamycin, ADM; 5-fluorouracil; 5-FU) have been commonly used for the adjuvant treatment of breast cancer. Recently, a combination of CEF (CPA; Epirubicin, EPI; 5-FU) has come to the stage of adjuvant setting, because the cardiotoxicity was reduced in EPI. In this study, we investigated the feasibility of 6 cycles of CEF (CPA 700 mg/m2 EPI 70 mg/m2, 5-FU 700 mg/m2; day 1 iv every 3-4 weeks) in the adjuvant treatment of primary breast cancer patients with nodal involvements. All 12 patients completed 6 cycles of CEF within 8 months. The median treatment duration was 6.2 months. More than Grade III side effects of neutropenia, nausea/vomiting and alopecia were observed in 7/12 (58.3%), 5/12 (41.7%) and 12/12 (100%), respectively. No serious side effects, including cardiotoxicity, were shown. CEF seems to be a feasible regimen as an adjuvant treatment for breast cancer.

AB - In Japan, 5-FU/5-FU derivatives or the combination therapy of CAF (cyclophosphamide, CPA; adriamycin, ADM; 5-fluorouracil; 5-FU) have been commonly used for the adjuvant treatment of breast cancer. Recently, a combination of CEF (CPA; Epirubicin, EPI; 5-FU) has come to the stage of adjuvant setting, because the cardiotoxicity was reduced in EPI. In this study, we investigated the feasibility of 6 cycles of CEF (CPA 700 mg/m2 EPI 70 mg/m2, 5-FU 700 mg/m2; day 1 iv every 3-4 weeks) in the adjuvant treatment of primary breast cancer patients with nodal involvements. All 12 patients completed 6 cycles of CEF within 8 months. The median treatment duration was 6.2 months. More than Grade III side effects of neutropenia, nausea/vomiting and alopecia were observed in 7/12 (58.3%), 5/12 (41.7%) and 12/12 (100%), respectively. No serious side effects, including cardiotoxicity, were shown. CEF seems to be a feasible regimen as an adjuvant treatment for breast cancer.

KW - Adjuvant chemotherapy

KW - CEF

KW - Epirubicin

UR - http://www.scopus.com/inward/record.url?scp=0030967716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030967716&partnerID=8YFLogxK

M3 - Article

C2 - 9126304

AN - SCOPUS:0030967716

VL - 24

SP - 679

EP - 683

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 6

ER -